ArticleRMD open2024
National burden of rheumatoid arthritis in Canada, 1990-2019: findings from the Global Burden of Disease Study 2019 - a GBD collaborator-led study.
Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- The Optimal Exercise Modality and Dose for Blood Pressure Management in Middle-Aged and Older Adults: A Systematic Review with Bayesian Model-Based, and Dose-Response Network Meta-Analysis of RCTs.Sports medicine (Auckland, N.Z.) · 2026Pooled it
- Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study.Rheumatology and therapy · 2026Article
- Identification and Experimental Validation of Key Biomarkers for Rheumatoid Arthritis Based on Bioinformatics Analysis and Machine Learning.Journal of inflammation research · 2026Article
- Changing physical activity behavior among individuals with inflammatory arthritis: an umbrella review of current behaviors, behavioral determinants, and behavior change interventions.BMC rheumatology · 2025Article
- Exploring herbal synergies in the management of rheumatoid arthritis: a multifaceted approach to inflammation and joint health.Inflammopharmacology · 2025Review
- Genetic Variations in Bitter Taste Receptors and COVID-19 in the Canadian Longitudinal Study on Aging.Biomedicines · 2025Article
- Association ofRheumatology and immunology research · 2025Article
- Association ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Incidence and prevalence of rheumatoid arthritis in Thailand based on National administrative health data and a comprehensive literature review.Scientific reports · 2025Review
- The broad range of self-management strategies that people with rheumatic and musculoskeletal conditions apply: an online survey using a citizen science approach.Rheumatology international · 2025Article
- Neutrophils: a Central Point of Interaction Between Immune Cells and Nonimmune Cells in Rheumatoid Arthritis.Clinical reviews in allergy & immunology · 2025Review
- Real-world trends in rheumatic disease rates among pregnancies in Ontario, Canada: A repeated cross-sectional study.PloS one · 2025Article
- Tongue feature-based model for assessing disease activity in patients with rheumatoid arthritis.Frontiers in pharmacology · 2025Article
- Article
- Exploring temporal trends and burden of traumatic shoulder dislocation: a global perspective.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objectives of this study were: (1) to describe burden of rheumatoid arthritis (RA) and trends from 1990 to 2019 using the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) data, (2) to describe age and sex differences in RA and (3) to compare Canada's RA burden to that of other countries.
methodsDisease burden indicators included prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs) and disability-adjusted life-years (DALYs). GBD estimated fatal and non-fatal outcomes using published literature, survey data and health insurance claims. Data were analysed by Bayesian meta-regression, cause of death ensemble model and other statistical methods. DALYs for Canada were compared with DALYs of countries with similarly high Socio-Demographic Index values.
resultsIn Canada, the RA prevalence rate increased by 27% between 1990 and 2019, mortality rate decreased by 27%, YLL rate decreased by 30%, YLD increased by 27% and DALY rate increased by 13%, all age standardised. The decline in RA mortality and YLL rates was especially pronounced after 2002. The disease burden was higher in females for all indicators, and DALY rates were higher among older age groups, peaking at age 75-79 years. Prevalence and DALYs were higher in Canada compared with global rates.
conclusionTrends in RA burden indicators over time and differences by age and sex have important implications for Canadian policy-makers, researchers and care providers. Early identification and management of RA in women may help reduce the overall burden of RA in Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.